Saquib Ahmad: Management of DVT and Follow-Up
Saquib Ahmad, General Practitioner at Khyber Medical Centre Madinat Zyed, posted on LinkedIn:
”Management of DVT and Follow-Up
1. Initial Anticoagulation (First 3 Months)
All patients with acute DVT require therapeutic anticoagulation for a minimum of three months.
2. Treatment Duration After the First 3 Months
The decision to continue, reduce, or stop anticoagulation depends on whether the DVT was provoked, unprovoked, or associated with a persistent risk factor. This step is the key determinant of long-term outcomes.
3. Anticoagulant Options for All Acute DVT
The following medications may be used for initial treatment.
- Apixaban: 10 mg twice daily for 7 days, followed by 5 mg twice daily
- Rivaroxaban: 15 mg twice daily for 21 days, followed by 20 mg once daily
- Dabigatran: 150 mg twice daily
- Edoxaban: 60 mg once daily (started after 5 days of heparin)
- Warfarin: use only if DOAC is unsuitable
Duration: Minimum treatment duration is 3 months for all cases of DVT.
Decide Duration After 3 Months (Most Important Step)
A. Provoked DVT (temporary risk factor)
Examples: surgery, trauma, immobilization, long flight, OCPs.
• Duration: 3 months only
• No need to extend therapy
• Do NOT check D-dimer for stopping decision
Recurrence risk: very low (1–3%/year)
B. Unprovoked DVT (no clear trigger)
• Duration: Extended therapy recommended
• Either full dose or reduced-dose DOAC
• Recurrence risk high (10% in 1st year)
D-dimer use:
Check D-dimer 4-6 weeks after stopping anticoagulation
• If high → restart DOAC long term
• If normal → optional observation
C. DVT with persistent risk factor (cancer, thrombophilia, chronic disease)
• Duration: Indefinite (lifelong) anticoagulation
• D-dimer not reliable → don’t use for decisions
DOAC Dosing for Long-Term Recurrence Prevention
(AKA “secondary prevention” or “extended therapy”)
After the first 3–6 months, reduce to secondary-prevention dose:
• Apixaban 2.5 mg BID
• Rivaroxaban 10 mg daily
These doses lower recurrence by 80–90% with minimal bleeding risk.
When to Repeat D-Dimer (Very Important)
Use ONLY in unprovoked DVT when deciding whether to stop anticoagulation.
When to measure:
- 4–6 weeks after fully stopping DOAC/warfarin
- Patient should be clinically stable
- No acute illness, no post-op period (false elevation)
How to interpret:
• Normal D-dimer: Indicates low recurrence risk and it is acceptable to remain off anticoagulation, with close follow-up.
• Elevated D-dimer: Indicates high recurrence risk and anticoagulation should be restarted or continued indefinitely using a DOAC.
DO NOT repeat D-dimer:
- In provoked DVT
- In cancer
- While patient is still on anticoagulation
- During pregnancy or postpartum
- After surgery or infection (false positives)
- Courtesy MRCP UK”
Stay updated with Hemostasis Today.
-
Apr 20, 2026, 12:14Yanki Yarman: Linking Genetic Variants to Clinical Outcomes in Thrombosis
-
Apr 20, 2026, 12:09Syed Sibtain Raza: White Blood Cells – Understanding Morphology for Better Diagnosis
-
Apr 20, 2026, 11:23Bastu Odoka: Jehovah’s Witness News on Transfusion… and a Question Worth Asking
-
Apr 20, 2026, 11:15William Aird: A Physiological Approach to Anemia
-
Apr 20, 2026, 10:59Eric Topol: Is the Interferon Pathway a Key Driver of Inflammaging and Aging
-
Apr 20, 2026, 10:47Emmanuel J Favaloro: Emerging Perspectives on Extracellular Vesicles in Hemophilia
-
Apr 20, 2026, 10:21Pierpaolo Di Micco: Honored to Join the ESVM Congress in Lausanne
-
Apr 20, 2026, 08:17Heghine Khachatryan: Key Takeaways from Day 1 – WFH 2026 World Congress
-
Apr 20, 2026, 08:10Justin Nelson-Deering։ Celebrating World Hemophilia Day in Pediatric Care